Search

Your search keyword '"Grohe, C."' showing total 37 results

Search Constraints

Start Over You searched for: Author "Grohe, C." Remove constraint Author: "Grohe, C." Publisher elsevier bv Remove constraint Publisher: elsevier bv
37 results on '"Grohe, C."'

Search Results

1. MA16.11 Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI)vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC

2. OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results

3. 296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

4. LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA

5. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report

7. P1.15-05 Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)

8. LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

9. Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”

10. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer

11. 1096O Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study

12. OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC

13. PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results

14. OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC

15. MO01.21 Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-Small Cell Lung Cancer who Received Prior Immunotherapy

16. 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

17. 1246P Hybrid capture-based assays in primary diagnostics of NSCLC patients: Results from the NEOlung study

18. 1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study

19. LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

21. Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection

22. Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance

27. Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)

28. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

29. Nintedanib plus docetaxel in routine clinical practice: VARGADO, a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape

30. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer: The FORCE trial

32. Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine

33. Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine

34. Investigating the Utility of Circulating-Free Tumour-Derived Dna (CTDNA) in Plasma for the Detection of Epidermal Growth Factor Receptor (EGFR) Mutation Status in European and Japanese Patients (PTS) with Advanced Non-Small-Cell Lung Cancer (ANSCLC): Assess Study

Catalog

Books, media, physical & digital resources